Ipsen Receives EMA Approval for Cometriq, Exelixis' Thyroid Cancer Treatment
Entry into the European Market and Partnership
The European Medicines Agency (EMA) has finalized its approval for Cometriq, a multitargeted tyrosine kinase inhibitor containing cabozantinib. This approval, achieved through the collaboration between Exelixis, the original developer, and Ipsen, which holds commercialization rights in Europe, marks a significant step in gaining access to the European market. Based on the licensing agreement signed in 2016, the two companies are solidifying their commercial presence in Europe and the global market. This approval provides Ipsen with the legal framework to reliably supply Cometriq to healthcare providers across Europe.
Clinical Value of Multitargeted Mechanism
Cometriq exhibits a potent pharmacological mechanism by simultaneously targeting and inhibiting RET, MET, and VEGFR2, key growth pathways in cancer cells. This multitargeted approach not only controls tumor growth but also comprehensively regulates angiogenesis and the microenvironment surrounding cancer cells, maximizing therapeutic efficacy. In particular, it demonstrates superior efficacy in inhibiting the acquisition of resistance by cancer cells through alternative pathways compared to conventional single-target therapies. By simultaneously inhibiting key receptors that drive cancer growth and metastasis, it is expected to provide patients with innovative opportunities for prolonged survival.
Data Proven by the EXAM Clinical Trial
The pivotal Phase 3 EXAM study (NCT00704730) demonstrated the excellent therapeutic efficacy of Cometriq, which served as the basis for this approval. In an evaluation of patients with advanced, unresectable, or metastatic medullary thyroid cancer, the median progression-free survival in the Cometriq group was 11.2 months, nearly three times longer than the 4.0 months in the placebo group. The hazard ratio of 0.28, representing a 72% reduction in the risk of disease progression or death, demonstrates high clinical value. Although the overall survival benefit did not meet the statistical significance criteria, the overwhelming difference in progression-free survival drove the final approval.
Addressing Unmet Needs and Future Pricing Prospects
The global market for medullary thyroid cancer treatments is currently estimated at $172.9 million, and the market penetration of Cometriq, which has received orphan drug designation, is expected. However, in the European market, the price negotiations with individual national health authorities and the reimbursement listing process after approval will be key determinants of final sales. In particular, it is expected that demonstrating a comparative advantage over existing treatments for the same indication will be necessary to secure high pricing and insurance coverage. Ipsen plans to establish customized strategies for each member state's pricing and insurance regulations to expedite the initiation of prescriptions.
This EMA final approval of Cometriq signifies a major milestone, officially expanding Ipsen and Exelixis' commercial territory into the European market, which is valued at approximately $172.9 million globally for medullary thyroid cancer. The progression-free survival of 11.2 months and hazard ratio of 0.28, demonstrated in the Phase 3 EXAM study, provide a strong clinical alternative to the existing standard of care, Caprelsa, and are positive signals for market share acquisition. According to the licensing agreement, Exelixis will receive $200 million in upfront payments from Ipsen, as well as up to $545 million in milestone payments and royalties of up to 26%, enhancing long-term financial stability. The results of future price negotiations in individual European countries and the success of reimbursement listing will be key short-term factors in determining the drug's early market establishment and the revenue growth of both companies.
Source: EMA (ema)